<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3813</journal-id>
<journal-title><![CDATA[Gaceta médica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. Méd. Méx]]></abbrev-journal-title>
<issn>0016-3813</issn>
<publisher>
<publisher-name><![CDATA[Academia Nacional de Medicina de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-38132024000600008</article-id>
<article-id pub-id-type="doi">10.24875/gmm.m24000906</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Descifrando el papel pronóstico de la inmunoglobulina G sérica en el síndrome de Guillain-Barré durante el tratamiento con inmunoglobulina intravenosa]]></article-title>
<article-title xml:lang="en"><![CDATA[Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galnares-Olalde]]></surname>
<given-names><![CDATA[Javier A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[Juan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez-Tobón]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Cañas]]></surname>
<given-names><![CDATA[Edwin S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Departamento de Enfermedades Neuromusculares ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>160</volume>
<numero>6</numero>
<fpage>648</fpage>
<lpage>653</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0016-38132024000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0016-38132024000600008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0016-38132024000600008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: El síndrome de Guillain-Barré (SGB) se asocia a una frecuencia de 20 % de discapacidad a largo plazo. Este estudio examina la fisiopatología del SGB y el papel de la inmunoglobulina (Ig) intravenosa.  Objetivo: Investigar si niveles elevados de inmunoglobulina G (IgG) tras la administración de Ig intravenosa están relacionados con mejor recuperación de la marcha independiente a los seis meses.  Material y métodos: Estudio observacional retroprospectivo de 42 pacientes. Los niveles de IgG se midieron antes del tratamiento y a los siete y 30 días postratamiento. Se empleó regresión binaria para analizar el impacto de factores individuales en el pronóstico y las secuelas. La curva de Kaplan-Meier evaluó la proporción de pacientes incapaces de caminar sin ayuda.  Resultados: El nivel medio basal de IgG fue de 832.25 mg/dL, que se incrementó a 3053.48 mg/dL al día 7 y disminuyó a 1091.72 mg/dL al día 30 postratamiento. Los pacientes con incremento &lt; 1945.5 mg/dL de IgG mostraron manifestaciones clínicas más graves, mayor necesidad de ventilación mecánica invasiva, disfunción autonómica y peores resultados en la marcha a los seis meses.  Conclusiones: El menor incremento de los niveles de IgG al día 7 postratamiento se asoció a peor pronóstico a los seis meses y menor probabilidad de marcha independiente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Guillain-Barré syndrome (GBS) is associated with 20% rate of long-term disability. This study explores the pathophysiology of GBS and the mechanism of intravenous immunoglobulin (IVIg).  Objective: To investigate whether elevated immunoglobulin G (IgG) levels following IVIg administration are linked to improved recovery of independent walking at 6 months.  Material and methods: A retro-prospective observational study was conducted. IgG levels were measured before treatment, 7- and 30-days post-initiation. Binary regression analysis assessed the impact of individual factors on prognosis and sequelae. The Kaplan-Meier curve was used to evaluate the proportion of patients who couldn´t walk unaided.  Results: Forty-two patients were included. The mean baseline IgG level was 832.25 mg/dl, increasing to 3053.48 mg/dl at 7 days and decreasing to 1091.72 mg/dl at 30 days. IgG increases at 7 days were categorized into quartiles. Patients with a low increase in IgG levels (&lt; 1945.5 mg/dl) at 7 days exhibited more severe clinical manifestations, including greater needs for invasive mechanical ventilation and increased autonomic dysfunction. Also had poorer walking outcomes at 6 months.  Conclusions: Lower increase in IgG levels at 7 days post-treatment is associated with a worse prognosis at 6 months, including a reduced likelihood of walking unaided.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Discapacidad]]></kwd>
<kwd lng="es"><![CDATA[IgG sérica]]></kwd>
<kwd lng="es"><![CDATA[Inmunoglobulina intravenosa]]></kwd>
<kwd lng="es"><![CDATA[Pronóstico]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de Guillain Barré]]></kwd>
<kwd lng="en"><![CDATA[Disability]]></kwd>
<kwd lng="en"><![CDATA[Serum IgG]]></kwd>
<kwd lng="en"><![CDATA[Intravenous immunoglobulin]]></kwd>
<kwd lng="en"><![CDATA[Prognosis]]></kwd>
<kwd lng="en"><![CDATA[Guillain Barré]]></kwd>
<kwd lng="en"><![CDATA[syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servir]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baughman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population incidence of Guillain-Barrésyndrome:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galnares-Olalde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[García-Grimshaw]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés-Ferrer]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Briseño-Godínez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[de-Sarachaga]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-BarréSyndrome in Mexico:an updated review amid the coronavirus disease 2019 ERA]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>2022</year>
<volume>74</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>121-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willison]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10045</numero>
<issue>10045</issue>
<page-range>717-27</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Swan]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulin for Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<volume>2014</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>CD002063</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verboon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment dilemmas in Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2017</year>
<volume>88</volume>
<page-range>346-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Colunga-Lozano]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[García-Trejo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Figueroa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-García]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán-Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barrésyndrome, a single center experience]]></article-title>
<source><![CDATA[J Clin Neurosci]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>292-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Latry]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Prost]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Delignat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lacroix-Desmazes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases]]></article-title>
<source><![CDATA[Transfus Clin Biol]]></source>
<year>2003</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>165-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Doorn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuitwaard]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Walgaard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[van Koningsveld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruts]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IVIG treatment and prognosis in Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2010</year>
<volume>30</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S74-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuitwaard]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[de Gelder]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tio-Gillen]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Hop]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[van Gelder]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[van Toorenenbergen]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2009</year>
<volume>66</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>597-603</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verboon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[van den Berg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cornblath]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Venema]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gorson]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Lunn]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Original research:Second IVIg course in Guillain-Barrésyndrome with poor prognosis:the non-randomised ISID study]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2020</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-21</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
